← All trials
NCT03537508
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2018
- Primary completion
- May 19, 2021
- Completion date
- May 19, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 2475
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- hepatitis a vaccine, inactivated
- measles, mumps, and rubella vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- inactivated varicella vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.